XOMA Corporation announced NIS793, an anti-TGF? monoclonal antibody licensed from the Company, has advanced to the Phase 3development stage, triggering a$35 million milestone payment from Novartis.? The Phase 3 trial (NCT04935359) is designed to assess the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo, in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).? In July, Novartis announced the U.S. Food and Drug Administration has granted Orphan Drug Designation to NIS793 in combination with standard of care chemotherapy for the treatment of pancreatic cancer. More information about the NIS793 Phase 3 clinical study, NCT04935359, titled ?Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)? can be found at ClinicalTrials.gov. Under the terms of the 2015 anti-TGF? development and commercialization agreement with Novartis, XOMA has the potential to earn up to $410 million in additional milestone payments.? Should Novartis receive regulatory approval to commercialize NIS793, XOMA will receive tiered royalties on net product sales that range from mid-single digit to low double digits. NIS793 is an investigational compound.? Efficacy and safety have not been established.? There is no guarantee that NIS793 will become commercially available.